Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 12/20 | 0.63 |
| ▸ | DRD4 | P21917 | 12/20 | 0.63 |
| ▸ | DRD3 | P35462 | 12/20 | 0.63 |
| ▸ | DRD1 | P21728 | 4/20 | 0.63 |
| ▸ | DRD5 | P21918 | 4/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.54 |
| ▸ | RELA | Q04206 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6282395 | 0.86 | DRD2 (0.65) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL22614226 | 0.85 | DRD2 (0.69) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL8864160 | 0.84 | DRD2 (0.72) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL5640879 | 0.84 | DRD2 (0.72) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL8864198 | 0.84 | DRD2 (0.72) | DRD2DRD4DRD3DRD1DRD5 | |
| Hydrochloric Acid SCHEMBL8864132 | 0.84 | DRD2 (0.62) | DRD2DRD4DRD3DRD1DRD5 | |
| Hydrochloric Acid SCHEMBL8864139 | 0.84 | DRD2 (0.62) | DRD2DRD4DRD3DRD1DRD5 | |
| Hydrochloric Acid SCHEMBL8864656 | 0.84 | DRD2 (0.62) | DRD2DRD4DRD3DRD1DRD5 | |
| Bromide SCHEMBL6281511 | 0.83 | DRD2 (0.70) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL8122472 | 0.81 | DRD2 (0.73) | DRD2DRD4DRD3DRD1DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1694664-A1 | 2- ( (2, 3-DIHYDROXYPROPYL) AMINOMETHYL) CHROMANE DERIVATIVES FOR USE AS BETA-3 ADRENORECEPTOR AGONISTS IN THE TREATMENT OF UROLOGICAL AND INFLAMMATORY DISORDERS | Bayer HealthCare AG (DE) | 2006-08-30 | — | — | EP | disclosed |
| US-20050222247-A1 | Chroman derivatives | BAYER HEALTHCARE AG (DE) | 2005-10-06 | — | — | US | disclosed |
| WO-2005056544-A1 | 2- ( (2, 3-DIHYDROXYPROPYL) AMINOMETHYL) CHROMANE DERIVATIVES FOR USE AS BETA-3 ADRENORECEPTOR AGONISTS IN THE TREATMENT OF UROLOGICAL AND INFLAMMATORY DISORDERS | BAYER HEALTHCARE AG (DE) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222247-A1 | Chroman derivatives | CHRM3, CHRNB3, ADRB3 | DRD2 1016/4885DRD4 1394/4885DRD3 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.